Characterization of C3 in C3 glomerulopathy

被引:41
|
作者
Sethi, Sanjeev [1 ]
Vrana, Julie A. [1 ]
Fervenza, Fernando C. [2 ]
Theis, Jason D. [1 ]
Sethi, Amit [3 ]
Kurtin, Paul J. [1 ]
Zhang, Yuzhou [4 ,5 ]
Smith, Richard J. H. [4 ,5 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA
[3] Mayo High Sch, Rochester, MN USA
[4] Carver Coll Med, Dept Internal Med, Div Nephrol, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA
[5] Carver Coll Med, Dept Pediat, Div Nephrol, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA
关键词
C3; glomerulonephritis; glomerulopathy; C3dg; complement; dense deposit disease; HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; MASS-SPECTRAL DATA; ALTERNATIVE PATHWAY; SEQUENCE DATABASES; COMPLEMENT; GLOMERULONEPHRITIS; DYSFUNCTION; PROTEOMICS;
D O I
10.1093/ndt/gfw290
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background: C3 glomerulopathy (C3G) is caused by overactivity of the alternative pathway of complement that results in bright glomerular C3 staining with minimal or no deposition of immunoglobulins on immunofluorescence microscopy. Laser microdissection and mass spectrometry of the two subtypes, C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), have identified C3 as the predominant glomerular complement protein, although lesser amounts of C9, C5, C6, C7 and C8 are detectable. C3 plays a central role in complement activity, with its proteolytic cleavage first generating C3a and C3b, followed by inactivation of C3b generating iC3b (which includes C3a and C3b), which undergoes further breakdown yielding C3c and terminal breakdown fragment C3dg. The composition of C3 breakdown products in C3G is not known. Methods: In this study, we chose six cases each of C3GN and DDD to analyze the composition of C3 deposits. We analyzed the amino acid sequence of C3 spectra detected by mass spectrometry to determine the relative abundance of C3 fragments in C3G. Thus we were able to determine the amino acid sequences mapping to the various C3 activation products including C3dg, C3a (C3a1 and a2), and C3b that are part of C3b/iC3b/C3c. Results: C3dg is the predominant cleavage product detected with the highest amino acid coverage. The remaining amino acids map to C3a (C3a1 and a2) and C3b. Amino acids mapping to C3a and C3f are absent. Taken together, the C3a and C3b amino acids represent iC3b prior to or after C3c cleavage of C3dg. The C3 spectra for both C3GN and DDD are surprisingly similar. Conclusion: The finding of large amounts of C3dg suggests that C3b deposition in the glomerulus is an active process triggered by thioester binding of C3b to the glycocalyx overlying the glomerular endothelial cells and glomerular basement membrane. Regulatory protein-mediated inactivation of C3b results in the generation of iC3b. After additional cleavages, mostly C3dg remains.
引用
收藏
页码:459 / 465
页数:7
相关论文
共 50 条
  • [31] Redefining C3 glomerulopathy: 'C3 only' is a bridge too far
    Larsen, Christopher P.
    Walker, Patrick D.
    KIDNEY INTERNATIONAL, 2013, 83 (02) : 331 - 332
  • [32] Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
    Wong, Edwin
    Nester, Carla
    Cavero, Teresa
    Karras, Alexandre
    Le Quintrec, Moglie
    Lightstone, Liz
    Eisenberger, Ute
    Soler, Maria Jose
    Kavanagh, David
    Daina, Erica
    Praga, Manuel
    Medjeral-Thomas, Nicholas R.
    Gaeckler, Anja
    Garcia-Carro, Clara
    Biondani, Andrea
    Chaperon, Frederique
    Kulmatycki, Kenneth
    Milojevic, Julie
    Webb, Nicholas J. A.
    Nidamarthy, Prasanna Kumar
    Junge, Guido
    Remuzzi, Giuseppe
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (12): : 2754 - 2764
  • [33] Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective?
    Caliskan, Yasar
    Torun, Ege Sinan
    Tiryaki, Tarik Onur
    Oruc, Aysegul
    Ozluk, Yasemin
    Akgul, Sebahat Usta
    Temurhan, Sonay
    Oztop, Nida
    Kilicaslan, Isin
    Sever, Mehmet Sukru
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (02) : 96 - 107
  • [34] Circulating Complement Levels and C3 Glomerulopathy
    Fervenza, Fernando C.
    Sethi, Sanjeev
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 9 (11): : 1829 - 1831
  • [35] Dense Deposit Disease and C3 Glomerulopathy
    Barbour, Thomas D.
    Pickering, Matthew C.
    Cook, H. Terence
    SEMINARS IN NEPHROLOGY, 2013, 33 (06) : 493 - 507
  • [36] The role of complement in C3 glomerulopathy
    Zipfel, Peter F.
    Skerka, Christine
    Chen, Qian
    Wiech, Thorsten
    Goodship, Tim
    Johnson, Sally
    Fremeaux-Bacchi, Veronique
    Nester, Clara
    Rodriguez de Cordoba, Santiago
    Noris, Marina
    Pickering, Matthew
    Smith, Richard
    MOLECULAR IMMUNOLOGY, 2015, 67 (01) : 21 - 30
  • [37] State of the art: C3 glomerulopathy and membranoproliferative glomerulonephritis. A consensus
    Hohenstein, B.
    Licht, C.
    Wiesener, M.
    Amann, K.
    Schaefer, F.
    Serka, C.
    Bergmann, C.
    Kirschfink, M.
    Zipfel, P.
    Hugo, C.
    NEPHROLOGE, 2015, 10 (04): : 327 - 340
  • [38] Treating C3 glomerulopathy with eculizumab
    Thomas Welte
    Frederic Arnold
    Julia Kappes
    Maximilian Seidl
    Karsten Häffner
    Carsten Bergmann
    Gerd Walz
    Elke Neumann-Haefelin
    BMC Nephrology, 19
  • [39] An Interdisciplinary Diagnostic Approach to Guide Therapy in C3 Glomerulopathy
    Schmidt, Tilman
    Afonso, Sara
    Perie, Luce
    Heidenreich, Karin
    Wulf, Sonia
    Krebs, Christian F.
    Zipfel, Peter F.
    Wiech, Thorsten
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum
    Al-Ghaithi, Badria
    Chanchlani, Rahul
    Riedl, Magdalena
    Thorner, Paul
    Licht, Christoph
    PEDIATRIC NEPHROLOGY, 2016, 31 (11) : 2079 - 2086